Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 6, 2013, Pages 336-347

  Van Wart, Scott A ^a,b   Shoaf, Susan E ^c   Mallikaarjun, Suresh ^c   Mager, Donald E ^b  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

cirrhosis; heart failure; hyponatremia; pharmacokinetics; tolvaptan

Indexed keywords

FUROSEMIDE; HYDROCHLOROTHIAZIDE; PLACEBO; SODIUM; TOLVAPTAN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD PUGH SCORE; COMPARTMENT MODEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; ELECTROLYTE BALANCE; FEMALE; HUMAN; HYPERVOLEMIA; HYPONATREMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OPEN STUDY; PARALLEL DESIGN; PHARMACOKINETICS; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL;

CIRRHOSIS; HEART FAILURE; HYPONATREMIA; PHARMACOKINETICS; TOLVAPTAN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, VASOPRESSIN; YOUNG ADULT;

EID: 84883740060     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1849     Document Type: Article

References (29)

1. Oghlakian G, Klapholz M,. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev 2009; 17: 10-15. doi: 10.1097/CRD.0b013e318190e72c.
2. Ishikawa SE, Schrier RW,. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol 2003; 58: 1-17.
3. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS,. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol 1985; 248 (3 Pt. 2): H396-H402.
4. Knepper MA, Wade JB, Terris J, et al,. Renal aquaporins. Kidney Int 1996; 49 (6): 1712-1717.
5. Lin M, Liu SJ, Lim IT,. Disorders of water imbalance. Emerg Med Clin North Am 2005; 23: 749-770.
6. Samsca™ (tolvaptan) tablets [package insert]. Rockville, MD. Otsuka America Pharmaceutical, Inc.; November, 2012.
7. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S,. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 2007; 47: 1498-1507.
8. Lee RC, Watkins ML, Patterson JH, et al,. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18.
9. 2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 2003; 107: 2690-2696.
10. Gheorghiade M, Gattis WA, O'Connor CM, et al,. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-1971.
11. 2-receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52 (19): 1540-1545. doi: 10.1016/j.jacc.2008.08.013.
12. Shoaf SE, Bricmont P, Mallikaarjun S,. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. Int J Clin Pharmacol Ther 2012; 50 (2): 150-156.
13. 2-receptor antagonist-pharmacology and clinical trials. Cardiovasc Drug Rev 2007; 25: 1-13.
14. Shoaf SE, Kim SR, Bricmont P, Mallikaarjun S,. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects. Eur J Clin Pharmacol 2012 May 15. DOI: 10.1007/s00228-012-1295-5.
15. Yi S, Jeon H, Yoon SH, et al,. Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men. J Cardiovasc Pharmacol 2012; 59 (4): 315-322. doi: 10.1097/FJC.0b013e318241e89c.
16. Shoaf SE, Ohzone Y, Ninomiya S, et al,. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol 2011; 51 (5): 761-769. doi: 10.1177/0091270010376193.
17. Shoaf SE, Bricmont P, Mallikaarjun S,. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol 2012; 73 (4): 579-587. doi: 10.1111/j.1365-2125.2011.04114.x.
18. Shammas FV, Dickstein K,. Clinical pharmacokinetics in heart failure. An updated review. Clin Pharmacokinet 1988; 15 (2): 94-113.
19. Woosley RL,. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am Heart J 1987; 114 (5): 1280-1291.
20. Naafs MA, van der Hoek C, van Duin S, Koorevaar G, Schopman W, Silberbusch J,. Decreased renal clearance of digoxin in chronic congestive heart failure. Eur J Clin Pharmacol 1985; 28 (3): 249-252.
21. Fukunami M, Matsuzaki M, Hori M, Izumi T, Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study. Cardiovasc Drugs Ther 2011; 25 (Suppl 1): S47-S56. doi: 10.1007/s10557-011-6348-y.
22. Berl T, Quittnat-Pelletier F, Verbalis JG, et al,. SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21 (4): 705-712. doi: 10.1681/ASN.2009080857.
23. Cárdenas A, Ginès P, Marotta P, et al,. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012; 56 (3): 571-578. doi: 10.1016/j.jhep.2011.08.020.
24. Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25 (Suppl 1): S33-S45. doi: 10.1007/s10557-011-6304-x.
25. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA,. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 2007; 50 (2): 213-222.
26. Beal SL, Sheiner LB, Boeckmann AJ,. NONMEM Users Guides. ICON Development Solutions: Ellicott City, MD, 2006.
27. Chen X, Mallikaarjun S, Wang Z, Bramer SL,. Population pharmacokinetic modeling of drugs exhibiting less than proportional increases in pharmacokinetics relative to increasing doses. Poster at PAGE meeting, 2002; Paris, France.
28. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13 (2): 143-151. doi: 10.1208/s12248-011-9255-z.
29. Mordenti J,. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75 (11): 1028-1040.